Cosopt drops 5 ml
Mundipharma
Mundipharma
Compound
Each ml contains
dorzolamide hydrochloride,
– which corresponds to the content of dorzolamide base 2%
timolol maleate
– which corresponds to the content of timolol base 0.5%
Auxiliary components
benzalkonium chloride (as 50% benzalkonium chloride solution), sodium citrate, mannitol, hyetellose (hydroxyethylcellulose), 1M sodium hydroxide solution, water for injections.
Properties
Antiglaucoma drug of combined composition. Contains two active ingredients: dorzolamide hydrochloride and timolol maleate, each of which reduces elevated intraocular pressure by reducing the secretion of intraocular fluid. The combined action of these substances in the composition of the drug leads to a more pronounced decrease in intraocular pressure.
Dorzolamide hydrochloride is a selective type II carbonic anhydrase inhibitor. Inhibition of carbonic anhydrase in the ciliary body leads to a decrease in the secretion of intraocular fluid, presumably due to a decrease in the formation of bicarbonate ions, which in turn leads to a slowdown in the transport of sodium and fluid.
Timolol maleate is a non-selective beta-blocker. Although the exact mechanism of action of timolol maleate in reducing intraocular pressure has not yet been established, a number of studies have shown a predominant decrease in formation, as well as a slight increase in fluid outflow.
Indications
Increased intraocular pressure
– with open-angle glaucoma;
– with pseudoexfoliative glaucoma with insufficient effectiveness of monotherapy.
Dosage and administration
Kosopt is prescribed 1 drop in the conjunctival sac of the affected eye (or both eyes) 2 times / day.
If Kosopt is prescribed as a replacement for another ophthalmic drug for the treatment of glaucoma, the latter should be discontinued the day before the start of Kosopt therapy.
In case of joint use with another topical ophthalmic preparation, Kosopt should be used at intervals of at least 10 minutes.
With nasolacrimal occlusion (closing of the eyelids) for 2 minutes after instillation of the drug, its systemic absorption decreases, which can lead to an increase in local action.
Contraindications
– hyperreactivity of the respiratory tract;
– bronchial asthma (including history);
– severe COPD;
– sinus bradycardia;
-SSSU;
– AV block II and III degree without a pacemaker;
– severe heart failure;
– cardiogenic shock; severe renal failure (CC <30 ml / min);
– hyperchloremic acidosis;
– dystrophic processes in the cornea;
-pregnancy;
– lactation period (breastfeeding);
-children and adolescents under 18 years of age (due to insufficient knowledge of efficacy and safety);
– Hypersensitivity to the components of the drug.
Precautionary measures
Like other topical ophthalmic preparations, Kosopt may be absorbed into the systemic circulation. Since timolol, which is part of the drug, is a beta-blocker, adverse reactions that develop with the systemic use of beta-blockers may occur with topical application of the drug.
When the first signs or symptoms of heart failure appear, the use of Cosopt should be discontinued.
Side effects
The most commonly observed side effects on the part of the organ of vision: burning sensation or itching in the eye, taste distortion, corneal erosion, conjunctival injection, blurred vision, lacrimation.
Storage method
Store at a temperature not higher than 15-30 degrees. After opening, store no longer than 28 days.
Package
The carton box holds a 5 ml bottle.